Stockscreener 앱 받기
1.07
0.93%
-0.01
시간 외 거래:
1.08
0.01
+0.93%
전일 마감가:
$1.08
열려 있는:
$1.08
하루 거래량:
1.52M
Relative Volume:
0.43
시가총액:
$388.84M
수익:
$1.21M
순이익/손실:
$-177.12M
주가수익비율:
-1.3375
EPS:
-0.8
순현금흐름:
$-162.37M
1주 성능:
-6.96%
1개월 성능:
-4.46%
6개월 성능:
+229.43%
1년 성능:
-34.36%
1일 변동 폭
$1.03
$1.09
1주일 범위
$1.03
$1.20
52주 변동 폭
$0.2836
$2.175
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
LXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.07 | 407.01M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 개시 | H.C. Wainwright | Buy |
| 2024-04-30 | 개시 | Leerink Partners | Outperform |
| 2023-03-07 | 개시 | Jefferies | Hold |
| 2022-08-12 | 개시 | Piper Sandler | Overweight |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 재확인 | Stifel | Buy |
| 2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-01 | 재확인 | Wedbush | Outperform |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2016-08-05 | 재확인 | Wedbush | Outperform |
| 2016-08-02 | 개시 | Citigroup | Buy |
| 2016-03-02 | 재확인 | Wedbush | Outperform |
| 2015-11-09 | 재확인 | Wedbush | Outperform |
| 2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
| 2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
Novel Pain Treatment Breakthrough: Lexicon's Pilavapadin Shows Promise for MS and Chemo Patients - Stock Titan
Combining price and volume data for Lexicon Pharmaceuticals Inc.Exit Point & Risk Controlled Swing Alerts - Newser
What is Lexicon Pharmaceuticals Inc.’s book value per shareJuly 2025 Review & Expert Verified Stock Movement Alerts - khodrobank.com
Can trapped investors hope for a rebound in Lexicon Pharmaceuticals Inc.July 2025 WrapUp & Verified Chart Pattern Trade Signals - Newser
Analyzing net buyer seller activity in Lexicon Pharmaceuticals Inc.Quarterly Trade Report & Daily Market Momentum Tracking - Newser
Lexicon Pharmaceuticals Inc. stock momentum explainedCPI Data & Daily Profit Maximizing Tips - Newser
Lexicon Pharmaceuticals' Strategic R&D Pivots and Licensing Catalysts in 2025 - AInvest
Lexicon Pharmaceuticals' Strategic Positioning in the Biopharma Sector - AInvest
Can Lexicon Pharmaceuticals Inc. generate free cash flow2025 Valuation Update & Weekly High Conviction Ideas - khodrobank.com
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 - The Manila Times
Lexicon Pharmaceuticals to Present Patient Insights on Diabetic Peripheral Neuropathic Pain at PAINWeek 2025 - Quiver Quantitative
30% of Diabetics Suffer Neuropathic Pain: Lexicon Study Reveals Impact on Daily Life at PAINWeek - Stock Titan
H.C. Wainwright reiterates Buy rating on Lexicon Pharmaceuticals stock at $4 - Investing.com
How to use a screener to detect Lexicon Pharmaceuticals Inc. breakouts2025 Performance Recap & High Accuracy Trade Alerts - Newser
Using Python tools to backtest Lexicon Pharmaceuticals Inc. strategiesEarnings Beat & Risk Controlled Swing Trade Alerts - Newser
Pattern recognition hints at Lexicon Pharmaceuticals Inc. upsideMarket Sentiment Report & Real-Time Chart Pattern Alerts - Newser
Update Recap: Can Lexicon Pharmaceuticals Inc. reach all time highs this year2025 Valuation Update & Real-Time Market Trend Scan - khodrobank.com
How to build a dashboard for Lexicon Pharmaceuticals Inc. stockMarket Trend Report & AI Optimized Trading Strategy Guides - Newser
Buybacks Report: What’s the MACD signal for Lexicon Pharmaceuticals Inc.Market Volume Summary & Technical Entry and Exit Alerts - khodrobank.com
Price action breakdown for Lexicon Pharmaceuticals Inc.Market Movement Recap & High Accuracy Swing Entry Alerts - Newser
Is Lexicon Pharmaceuticals Inc. meeting your algorithmic filter criteriaLong Setup & Safe Capital Growth Stock Tips - Newser
28% Heart Failure Risk Reduction: Lexicon's Sotagliflozin Proves Equally Effective in Elderly Patients Over 75 - Stock Titan
Ideas Watch: Is Lexicon Pharmaceuticals Inc. benefiting from innovation trendsJuly 2025 Market Mood & Community Trade Idea Sharing Platform - khodrobank.com
What is Lexicon Pharmaceuticals Inc.’s valuation compared to sectorPortfolio Return Summary & Safe Capital Growth Trade Ideas - khodrobank.com
Can Lexicon Pharmaceuticals Inc. ride the EV waveRate Cut & Daily Entry Point Alerts - khodrobank.com
What is Lexicon Pharmaceuticals Inc.’s TAM (Total Addressable Market)July 2025 Intraday Action & Real-Time Volume Trigger Notifications - khodrobank.com
Analysts Backtest Strategies on Lexicon Pharmaceuticals Inc. With Promising Results getLinesFromResByArray error: size == 0 - kangso.co.kr
What’s the RSI of Lexicon Pharmaceuticals Inc. stockQuarterly Profit Report & Real-Time Buy Zone Alerts - khodrobank.com
MACD Cross Could Confirm Trend in Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & Target Return Focused Stock Picks - beatles.ru
Visual analytics tools that track Lexicon Pharmaceuticals Inc. performanceMarket Growth Report & Fast Momentum Stock Entry Tips - Newser
Measuring Lexicon Pharmaceuticals Inc.’s beta against major indices2025 Buyback Activity & Reliable Momentum Entry Alerts - Newser
Should you hold or exit Lexicon Pharmaceuticals Inc. nowJuly 2025 Macro Moves & Safe Capital Growth Stock Tips - Newser
Heatmap analysis for Lexicon Pharmaceuticals Inc. and competitors2025 Market WrapUp & Weekly High Return Stock Forecasts - Newser
Can momentum traders help lift Lexicon Pharmaceuticals Inc.July 2025 Recap & Expert Curated Trade Ideas - Newser
Strategies to average down on Lexicon Pharmaceuticals Inc.July 2025 Retail & Weekly High Return Opportunities - Newser
Will Lexicon Pharmaceuticals Inc. outperform tech stocksJuly 2025 Summary & Stepwise Trade Signal Guides - sundaytimes.kr
Real time alert setup for Lexicon Pharmaceuticals Inc. performanceIndex Update & Reliable Price Breakout Alerts - Newser
Will Lexicon Pharmaceuticals Inc. face regulatory challenges2025 Short Interest & Step-by-Step Swing Trade Plans - 한국정경신문
Top chart patterns to watch in Lexicon Pharmaceuticals Inc.July 2025 EndofMonth & Weekly Momentum Stock Picks - Newser
Exit strategy if you’re trapped in Lexicon Pharmaceuticals Inc.Trade Risk Report & Growth Oriented Trade Recommendations - Newser
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
렉시콘 파마슈티컬스 주식 (LXRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
| BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
| Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
| DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
1.75%
1.11%
자본화:
|
볼륨(24시간):